For example, cyclin-dependent kinases 4/6 inhibitors, including palbociclib, ribociclib, and abemaciclib, have been approved for the treatment of patients with hormone receptor-positive and human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer [7]. This evidence concerns the gene ERBB2 and breast cancer.